Fiore (Amd Lazio): "Monitoraggio glicemia a bassa tecnologia vera svolta per diabete"
(Adnkronos) - Fiore: “Questa nuova modalità di poter utilizzare questi dispositivi per il monitoraggio del glucosio a bassa tecnologia rappresenta un passaggio epocale perché ci dà la possibilità di monitorare il profilo glicemico dei pazienti in una sorta di procedura quotidiana per tutto il giorno. Con questi dispositivi possiamo ridefinire gli obiettivi di cura e fare una terapia più appropriata”. Così Vincenzo Fiore, presidente Amd Lazio, intervenuto alla presentazione delle linee prescrittive dei presidi per il monitoraggio glicemico presso la Sede nazionale della Società italiana di diabetologia a Roma.
Category
🗞
NewsTranscript
00:00We have at our disposal a new way, which is to be able to use these devices for low-tech glucose monitoring in patients in insulin therapy,
00:15also in monosubstantiation, also in those who do less than three substantiations a day.
00:27It is an epochal step, because it gives us the opportunity to monitor the patient's glycemic profile in a sort of daily procedure,
00:45for the whole day and not in an instantaneous way, and in a weekly and weekly model, depending on the type of sensor.
00:55From a patient's point of view, it is fundamental, because it changes, but there is a need for a clinical motivation that explains the risk of hypoglycemia for the use of these devices.
01:15In patients in insulin therapy, we expect that it will certainly improve the progress of the disease.
01:23It is a generational change, because in many cases, especially in the peripheries of the territory,
01:30often and willingly the non-use of these devices still leads to the traditional use of the glycemic diary, which is outdated.
01:41Currently, with these devices, we can better redefine the objectives of care and, consequently, make a better, more appropriate therapy.
01:52The other really innovative aspect is the opening, for which I thank Dr. Messurati, the Association of Patients in the Linear Figure of Lemona,
02:05and Professor Nicola Napoli, President of SID.
02:09I thank for the opening of type 2 diabetes, for the use of these devices in type 2 patients,
02:17who have a high risk of cardiovascular disease and are in therapy with glyphosate and or analogues of GLP1 receptor agonists.
02:24This is an epochal change, because it gives us the opportunity to verify, to improve the educational process
02:33and to make the patient aware of the state of the disease.
02:38In that period, that is, a month, the patient can verify how the glycemic profile changes in relation to what he does,
02:50both from a physical point of view and from the point of view of the nutrients he eats.
02:55These are advantages, I repeat, that are tangible both in the course of the day or in the period of measurement on the glycemic profile,
03:08because they allow us to verify if there is a trend of hyperglycemia in the morning, or pre-prandial, or post-prandial, or at night,
03:18and therefore to immediately correct the patient's physical condition in insulin therapy.
03:25For others, it gives us an increased awareness of the state of the disease,
03:31but above all, I expect, in the long term, an advantage in terms of glycate and in terms of reduction of acute cardiovascular complications,
03:42which are often caused by hypoglycemic spike or nadir states, or even in terms of chronic complications.
03:51And finally, think for the most fragile patients, in some conditions, how useful they can be for the gatekeepers.